Agent | Mechanism | Cancer cell lines/tumor models | Agents potentiated | References |
---|---|---|---|---|
ABT-888 | PARP inhibition | Breast, lung, ovarian, colon, melanoma, glioma | TMZ, cisplatin, carboplatin, irinotecan, cyclophosphamide, IR | |
AG14361 | PARP inhibition | Lung, colorectal | TMZ, topotecan, irinotecan, IR | [56] |
CEP-6800 | PARP inhibition | Colon, GBM, NSCLC | TMZ, irinotecan, cisplatin | [58] |
CEP-8983 | PARP inhibition | GBM, colon, rhabdomyosarcoma, neuroblastoma | TMZ, camptothecin, irinotecan | [85] |
INO-1001 | PARP inhibition | Breast, GBM, sarcoma | TMZ, doxorubicin, IR | |
Lithocholic acid | DNA pol-β inhibition | BRCA2-deficient Chinese hamster ovary cells | TMZ | [59] |
Methoxyamine | AP site binding | Colon | TMZ, BCNU | [68] |